期刊文献+

老年冠心病患者血清sICAM-1、CRP、sVAP-1的异常表达及临床意义

Abormal expressions of sICAM-1,sVAP-1 and CRP in the elderly patients with coronary heart disease and their clinical significances
下载PDF
导出
摘要 目的:探讨可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管黏附蛋白-1(sVAP-1)、C反应蛋白(CRP)等相关指标在老年急性心肌梗死患者及稳定性心绞痛患者体内表达及其临床意义。方法:通过ELISA法分别检测老年急性心肌梗死患者、稳定性心绞痛患者及健康老年人体内sICAM-1、sVAP-1、CRP水平并对各指标作组间比较以分析三组之间差异。结果:三指标以急性心肌梗死患者体内水平为最高,与稳定性心绞痛患者及健康老年人之间的差异有显著性(P<0.01);心绞痛组三指标较正常对照组差异有显著性(P<0.01)。结论:稳定性心绞痛患者、心肌梗死患者血清sVAP-1、sICAM-1、CRP异常表达,其表达水平与疾病严重程度有关,sVAP-1、sICAM-1、CRP参与了心血管疾病的形成与发展。 Objective:To investigate and compare the expressions of soluble interceUular adhesion molecule-1 (sICAM-1),soluble vascular adhesion protein-1 (sVAP-1) and C-reactive protein (CRP) in the elderly patients with stable angina pectoris and acute myocardial infarction and their clinical significances.Methods:The levels of sICAM-1,sVAP-1 and CRY in acute myocardial infarction group, stable angina pectorics group and normal control group were respectively measured by ELISA,and compared among them.Results:The levels of sICAM-1,sVAP-1 and CRY were highest in the acute myocardical infarction group compared with those in the stable angina pectofis group and normal control group,with significant difference (P〈0.01),and lowest in the control group.The difference between stable angina pectoris group and control group was significant (P〈0.01).Conclusion:There were abnormal expressions of sICAM-1,sVAP-1 and CRY in the eMerly patients with stable angina pectoris or acute myocardial infarction,their levels of expression were associated with the serious degree of this disease.sICAM-1,sVAP-1 and CRY participated in the formation and development of cardiovascular diseases.
出处 《现代医药卫生》 2005年第24期3357-3359,共3页 Journal of Modern Medicine & Health
基金 江苏省镇江市科技局SH2002029
关键词 稳定性心绞痛 急性心肌梗死 可溶性细胞间黏附分子 可溶性血管黏附蛋白 C反应蛋白 Stable angina pectofis Acute myocardial infarction sICAM-1 sVAP-1 CRP
  • 相关文献

参考文献2

二级参考文献15

  • 1脑卒中患者临床神经功能缺损程度评分标准(1995)[J].中华神经科杂志,1996,29(6):381-383. 被引量:15727
  • 2Grundy SM,Bazzarre T, cleeman J, et al. Prevention conference V: beyond secondary prevention., identifying the high-risk patient for primary prevention[J]. Circulation,2000,101 :e3-e11.
  • 3Roberts WL, Mouton L,Law TC, et al. Evluation of nine anomated high sensitivity C-reactive protein methods : implications for clinical and epidemiological applications[J].Clin Chem,2001,47:418-423.
  • 4Vicky A Legrys. The use of high sensitiveity c-reactive protein in assessing the risk for coronary heart disease[J]. Clin Lab Sci, 2001,14(4) :243-246.
  • 5Morrow DA,Ridker PM. C-reactive protein,inflammation and coronary risk[J]. Med Clin North Am,2000,84:149-161.
  • 6Mublestein JB, Horne BD,Carlquist JF, et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease[J]. Circulation, 2000,102 : 1917-1923.
  • 7Cavusoglu Y,Gorenek B,Alpsoy S, et al. Evaluation of Creactive protein, fibrinogen and antithrombin-2 as risk factor for coronary artery disease[J]. Isr Med Assoe J,2001,3:13-16.
  • 8Rafac N, Ridker PM. High-sensitivity C-reactive protein:a novel and promising marker of coronary heart disease[J]. Clin Chem, 2001,47 : 403-411.
  • 9Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease[J]. Circulation, 2001,103:1813-1818.
  • 10Bautista LE, Lopez JP, Vera LM, et al. hs C-reactive protein an independent risk factor for essential hypertension[J]. J Hypertens, 2001,19:857-861.

共引文献132

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部